Filing Summary
Entity note: The request identifies Pharmacyte Biotech, Inc., but the supplied filing is for Nuvilex, Inc. This summary reflects the filing text provided, not a Pharmacyte filing.
Business Context and Reporting Period
Nuvilex reported for the three months ended July 31, 2014, with comparison to the three months ended July 31, 2013. The company described its focus as biotechnology, centered on its Cell-in-a-Box live-cell encapsulation technology for cancer and diabetes. Its acquisition of Bio Blue Bird provided cancer-treatment licensing rights; it also held a 14.5% interest in SG Austria and an exclusive worldwide diabetes license.
Financial Results and Liquidity
| Metric | Three months ended July 31, 2014 | Three months ended July 31, 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1,583,160 | $1,400,691 |
| Operating loss | $1,583,160 | $1,400,691 |
| Net loss | $1,584,824 | $4,666,367 |
| Basic loss per share | $0.00 loss | $0.01 loss |
| Net cash used in operations | $786,814 | $159,674 |
| Cash at period end | $2,896,939 | $206,038 |
Gross margin is not meaningful because there were no product sales or cost of revenues. Cash declined by $719,531 from April 30, 2014. At July 31, current assets were $3,069,072 and current liabilities were $371,386. Total liabilities were $371,386; these included $125,142 owed to an officer and $36,612 of accrued related-party interest. The officer loan bears 8% interest and is due on demand. The filing reports no long-term debt.
Changes Versus the Prior Comparable Period
- Net loss narrowed by $3,081,543, mainly because the prior-year quarter included a $3,973,795 loss on debt settlement and a $640,000 loss on preferred-stock conversion, partly offset by a $1,358,470 gain on debt forgiveness.
- Operating expenses rose by $182,469. Sales and marketing, legal and professional, and general and administrative expenses increased; compensation expense fell by $948,709, primarily because fewer shares were issued for compensation.
- Operating cash use increased by $627,140 year over year. Financing provided $67,283 in the 2014 quarter, compared with $1,735,259 in the prior-year quarter.
Outlook, Risks, and Unusual Items
- Management said cash on hand was sufficient to fund operations through July 31, 2015, but also stated that substantial additional capital would be needed, future losses were expected, and failure to raise funds could delay or end planned operations.
- Planned work included preparations for a Phase 2b pancreatic cancer trial in Australia, U.S. studies on pancreatic-cancer symptoms, diabetes preclinical research, and investigation of cannabinoid-based treatments. The filing provides no specific trial start dates, regulatory milestones, or revenue guidance.
- The company terminated its Lincoln Park stock purchase agreement on May 28, 2014. The agreement had contemplated up to $25 million in additional equity funding; termination resulted in issuance of 1,062,500 shares recorded as $297,500 of non-cash expense.
- A May 28 Chardan agreement provided for efforts to sell up to $50 million of common stock, subject to market conditions and company discretion, with fees and warrant consideration. The filing does not report proceeds from this arrangement during the quarter.
- During the quarter, the company issued shares for compensation, warrant exercises, and stock payables, and sold shares for cash. As of July 31, 710,356,214 common shares were issued and outstanding; the filing separately reports 710,020,918 shares as of September 15, 2014.
- Management reported disclosure controls were effective as of July 31, 2014. The company reported no material pending legal proceedings and no material changes to the risk factors in its 2014 annual report.
Key Investor Verification Points
- Confirm the issuer identity and reporting period, given the mismatch between the requested company and the Nuvilex filing supplied.
- Assess the reliability of management’s stated cash runway and the company’s ability to secure financing, given continuing operating cash burn and dependence on external capital.
- Verify the status, funding, timing, and regulatory requirements for the planned cancer and diabetes research and clinical programs.
- Review potential dilution from share issuances, warrants, the Chardan arrangement, and the difference between the July 31 and September 15 share counts.
- Check the valuation work still underway for the 14.5% SG Austria interest and contingent payments under the diabetes license; the filing says asset values may be adjusted after those valuations.